Home News Room Glossary Site Map Healthcare Professionals



Press Releases

Click on the headlines below to read recent news on bladder symptoms and VESIcare

1/19/05 - VESIcare (solifenacin succinate) now available nationwide in US (PDF)

11/22/04 - FDA Approves VESIcare® (solifenacin succinate) for the Treatment of Overactive Bladder (PDF)



Press Materials

Overactive Bladder Backgrounder (PDF)
Infographic (PDF)
Product Photo





Important Safety Information
VESIcare is for urgency, frequency, and leakage (overactive bladder). VESIcare is not for everyone. If you have certain types of stomach, urinary, or glaucoma problems, do not take VESIcare. While taking VESIcare, if you experience a serious allergic reaction, severe abdominal pain, or become constipated for three or more days, tell your doctor right away. In studies, common side effects were dry mouth, constipation, blurred vision, and indigestion.
Complete Prescribing Information for VESIcare

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Acrobat
Astellas